Literature DB >> 30635476

Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.

Bruce A Cohen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30635476     DOI： 10.1212/WNL.0000000000006924

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

1.  Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.

Authors:  Mariano Marrodan; Julia Laviano; Sofía Oneto; Fabricio M Reino; Ricardo Delorme; Florencia Fornillo; José Férnandez; Jorge Correale
Journal:  Neurol Sci       Date:  2021-06-01       Impact factor: 3.307

2.  Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.

Authors:  Nicola Capasso; Raffaele Palladino; Vincenza Cerbone; Antonio Luca Spiezia; Bianca Covelli; Antonia Fiore; Roberta Lanzillo; Antonio Carotenuto; Maria Petracca; Lucia Stanziola; Giulia Scalia; Vincenzo Brescia Morra; Marcello Moccia
Journal:  J Neurol       Date:  2022-09-01       Impact factor: 6.682

3.  Severe Delayed-Onset Neutropenia Induced by Ocrelizumab.

Authors:  Jonatha Baird-Gunning; James Yun; William Stevenson; Karl Ng
Journal:  Neurohospitalist       Date:  2020-07-09

Review 4.  Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.

Authors:  Tyler Ellis Smith; Ilya Kister
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-19       Impact factor: 5.081

Review 5.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

Review 6.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

7.  Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.

Authors:  Nabil Seery; Sifat Sharmin; Vivien Li; Ai-Lan Nguyen; Claire Meaton; Roberts Atvars; Nicola Taylor; Kelsey Tunnell; John Carey; Mark P Marriott; Katherine A Buzzard; Izanne Roos; Chris Dwyer; Josephine Baker; Lisa Taylor; Kymble Spriggs; Trevor J Kilpatrick; Tomas Kalincik; Mastura Monif
Journal:  CNS Drugs       Date:  2021-04-13       Impact factor: 5.749

8.  Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report.

Authors:  Robin Rauniyar; Rahul Rauniyar; Ankita Agrawal; Shikha Yadav; Sreekant Avula
Journal:  Clin Case Rep       Date:  2022-01-19

9.  Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.

Authors:  Reza Zonozi; Zachary S Wallace; Karen Laliberte; Noah R Huizenga; Jillian M Rosenthal; Eugene P Rhee; Frank B Cortazar; John L Niles
Journal:  Arthritis Rheumatol       Date:  2020-12-29       Impact factor: 10.995

Review 10.  Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators.

Authors:  Elaheh Kordzadeh-Kermani; Hossein Khalili; Iman Karimzadeh; Mohammadreza Salehi
Journal:  Infect Drug Resist       Date:  2020-02-18       Impact factor: 4.003
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.